DELCATH SYSTEMS FILES FIRST QUARTER 2007 10-Q AND SHELF REGISTRATION

STAMFORD, Conn.--May 10, 2007--Delcath Systems, Inc. (Nasdaq: DCTH) today announced today that it has filed its Form 10-Q for the quarter ended March 31, 2007 with the U.S. Securities and Exchange Commission (SEC). Following option exercises by an outgoing Director in the quarter, cash and equivalents plus certificates of deposit totaled approximately $8.1 million as of March 31st, 2007. The net loss for the three month period was $1.27 million, up $89,976 from the prior year, largely due to a non-recurring charge in connection with a settled lawsuit.

The 10-Q also announced the resolution of a separate lawsuit brought by the company and its former CEO against an individual. The lawsuit was dismissed in the United States District Court for the Northern District of Georgia and the defendant was granted recovery of its costs. "The resolution of the two lawsuits involving Delcath was a stated priority of Delcath's new management, and will allow us to better focus our efforts and resources on the approval and expanded development of our technology," stated Mr. Richard L. Taney, President and Chief Executive Officer of Delcath.

Delcath announced that simultaneous with the 10-Q, it filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). Pursuant to the S-3 filing, Delcath may issue common or preferred stock, warrants, or debt securities from time to time, in an aggregate amount of up to $17.2 million. While the Company has no current plans to access the capital markets, the shelf registration statement, once declared effective by the SEC, would allow Delcath to be in a position to access the capital markets based on market conditions and to address the Company's future capital needs.

The terms of any future offering will be established at the time of the offering, and any proceeds will be used for general corporate purposes, including without limitation the funding of our clinical research and development programs, the clinical development of our technology, capital expenditures and working capital needs.

Mr. Richard L. Taney, President and Chief Executive Officer of Delcath, commented, "Our company has made a strategic decision to put a shelf in place so that in the future Delcath can be opportunistic with regard to accessing the capital markets and can be in a better position to attract institutional investors. With over $8 million in cash, we believe we have sufficient capital to fund operations for the coming year, but feel it is important for the company to have the flexibility to raise funds at advantageous terms. We are extremely optimistic about the prospects for our company, and believe the decision to file this S-3 puts us in a position to quickly access capital at favorable terms should capital be needed to expand or accelerate the development and commercial approval of our technology."

This press release is not an offer to sell or the solicitation of an offer to buy nor shall there be any sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the form 10-Q and the shelf registration statement as filed with the SEC on Form S-3 may be obtained at the SEC's website at www.sec.gov, or through the Investor Relations section of the Delcath's website at www.delcath.com.

About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.